



201 Technology Drive • Irvine • California • 92618
Telephone: (949) 450-5400
Facsimile: (949) 450-5300
Email: IR@endocare.com
Website: www.endocare.com

FOR RELEASE April 24, 2007 at 6:00 am EDT

Investor Contact:

Matt Clawson
Allen & Caron, Inc.
(949) 474-4300
matt@allencaron.com

Media Contact:

Len Hall
Allen & Caron, Inc.
(949) 474-4300
len@allencaron.com

For Additional Information:

Craig T. Davenport, CEO
Michael R. Rodriguez, CFO
Endocare, Inc.
(949) 450-5400

**ENDOCARE SETS DATE FOR 2007 FIRST QUARTER
RESULTS RELEASE AND CONFERENCE CALL**

IRVINE, CA (April 24, 2007) . . . Endocare, Inc. (OTC BB: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, plans to issue a press release announcing its financial results for the first quarter ended March 31, 2007, before the market opens on Thursday, May 3, 2007, and to host a conference call to be webcast live on the Company's website (www.endocare.com/investors/webcasts.php) at 11:00 a.m. Eastern Time that same day.

Web participants are encouraged to go to the Company's website (www.endocare.com/investors/webcasts.php) at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. The online archived replay will be available immediately following the conference call at www.endocare.com/investors/webcasts.php.

About Endocare

Endocare, Inc. (www.endocare.com) is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

###